Chemo plus immunotherapy after lung surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study looks at whether adding an immunotherapy medicine (camrelizumab) to standard chemotherapy after lung surgery can help prevent lung cancer from coming back. It is for people with stage IIA–IIIA non-small cell lung cancer who cannot use targeted (mutation-based) adjuvant therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You will sign a consent form before any study steps
- Your lung cancer was surgically removed, and the post-surgery stage is IIA, IIB, or IIIA
- You cannot receive targeted (mutation-focused) adjuvant therapy
- You’re between 18 and 80 years old, and you can recover within 3–8 weeks after surgery to start treatment
- You have not had any prior chemotherapy for non-small cell lung cancer before joining
- Your blood tests, liver, and kidney tests are within required ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug camrelizumab to standard chemotherapy before surgery for people with stage IIIA-IIIB non-small cell lung cancer. The goal is to see if this combination shrinks tumors more effectively before removal.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This trial tests adding the immunotherapy drug Adebrelimab to standard chemotherapy before surgery for people with stage II or III non-small cell lung cancer (the most common type) that can be removed. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This study tests whether adding a new immunotherapy drug (ivonescimab or penpulimab) to standard chemotherapy before surgery helps people with early-stage lung cancer. It's for people whose cancer can be surgically removed and who haven't had treatment yet.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.